Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast

Myomo Reports First Quarter 2024 Financial Results


Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2024.

Financial and operational highlights for the first quarter of 2024 include the following (all comparisons are with the first quarter of 2023):

Management Commentary

"First quarter revenue reflects our focus on patients with traditional insurers with a history of payment, while temporarily accepting lower pricing from CMS' billing contractors known as the DME MACs. We expect growth to increase during the second quarter as we ship MyoPros to Medicare Part B beneficiaries following the publication of reimbursement fees by the Centers for Medicare and Medicare Services ("CMS") on April 1, 2024," said Paul R. Gudonis, Myomo's chairman and chief executive officer. "Our record backlog entering the second quarter includes 83 Medicare Part B patients, which will contribute to our expected revenue growth in the quarter."

Financial Results

 

For the Three Months
Ended March 31,

 

Period-
to-Period
Change

 

 

2024

 

2023

 

$

 

%

 

Product revenue

$

3,754,389

 

$

3,446,708

 

$

307,681

 

 

9

%

Cost of revenue

 

1,455,345

 

 

1,139,074

 

 

316,271

 

 

28

%

Gross profit

$

2,299,044

 

$

2,307,634

 

$

(8,590

)

 

(0

)%

Gross margin %

 

61.2

%

 

67.0

%

 

 

 

-5.8

%

Revenue for the first quarter of 2024 was $3.8 million, up 9% compared with the first quarter of 2023. Growth in revenue was driven by a higher number of revenue units, offset by a lower average selling price ("ASP"). ASP in the first quarter of 2024 was affected by underpayments from CMS' billing contractors, known as the DME MACs for lump sum reimbursement compared to amounts the Company is entitled to be reimbursed after the publication of the new pricing effective April 1, 2024. Myomo recognized revenue on 91 MyoPro units in the first quarter of 2024, up 14% compared with the same quarter a year ago.

Gross margin for the first quarter of 2024 was 61.2%, compared with 67.0% for the first quarter of 2023. The decrease was driven primarily by a lower ASP, a higher warranty reserve and material and other cost increases, offset by lower royalty expense.

Operating expenses for the first quarter of 2024 were $6.2 million, an increase of 24% compared with the first quarter of 2023. The increase was driven primarily by higher R&D spending due to headcount growth and outside engineering services to accelerate the completion of product development projects, higher payroll in the Company's clinical, reimbursement and human resources functions due to headcount increases to support increases in capacity, and higher advertising costs. Advertising spending of $0.8 million increased 14% from the first quarter of 2023. Cost per pipeline add was $1,597, an increase of 1% from the first quarter of 2023, but down 29% sequentially.

Operating loss for the first quarter of 2024 was $3.9 million, compared with an operating loss of $2.7 million for the first quarter of 2023. Net loss for the first quarter of 2024 was $3.8 million, or $0.10 per share, compared with a net loss of $2.6 million, or $0.11 per share, for the first quarter of 2023.

Adjusted EBITDA for the first quarter of 2024 was $(3.5) million, compared with $(2.5) million for the first quarter of 2023. A reconciliation of GAAP net loss to this non-GAAP financial measure appears below.

Operations Update

The MyoPro pipeline included 1,112 patients as of March 31, 2024, compared with 855 patients as of March 31, 2023, an increase of 30%. There were a record 493 patients added to the pipeline during the first quarter of 2024, an increase of 12% compared with the first quarter of 2023. The pipeline at the end of the first quarter included 230 Medicare Part B beneficiaries.

Backlog was a record 275 units as of March 31, 2024, up 56% compared with March 31, 2023. Backlog included 83 Medicare Part B patients who have received a MyoPro with claims filed and patients who have been qualified for delivery based on receipt of appropriate medical documentation.

Centers for Medicare & Medicaid Services Update

On April 1, 2024, final fees were published by CMS for its Healthcare Common Procedure Coding System ("HCSPS") codes L8701 and L8702 of $33,480.90 and $65,871.74, respectively. On May 6, 2024, the Company announced that authorizations for lump sum reimbursement for MyoPros delivered to Medicare Part B beneficiaries in April, based on the newly published fee schedule, had been received from all four of the DME MACs, with a number of payments having been received.

Cash Position

Cash, cash equivalents and short-term investments as of March 31, 2024 were $11.0 million, Cash used in operating activities was $3.2 million for the first quarter of 2024, compared to $1.8 million for the first quarter of 2023. The Company believes it has sufficient liquidity for at least the next 12 months from today.

Business Outlook

"Given our backlog, we're in a position to generate more than $5.0 million in product revenue in the second quarter," added Mr. Gudonis. "We're making progress on our capacity expansion plans, hiring approximately 20 people during the first quarter. We have the opportunity to generate between $28 million and $30 million in revenue in 2024, presuming that we meet our hiring goals and that there are no supply chain or other unexpected disruptions. We expect to have a better line of sight into this forecast by the time we report our second quarter financial results. We continue to believe that reaching operating cash flow breakeven on a quarterly basis by the fourth quarter of 2024 is achievable."

Conference Call and Webcast

Myomo will hold a conference call today at 4:30 p.m. Eastern time to discuss these results and answer questions. Participants are encouraged to pre-register for the call at this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time including up to and after the start of the call. Those unable to pre-register may participate by dialing 844-707-6932 (U.S.) or 412-317-9250 (International). A webcast of the call will also be available at Myomo's Investor Relations page at http://ir.myomo.com/.

A replay of the webcast will be available beginning approximately one hour after the completion of the live conference call at http://ir.myomo.com/. A dial-in replay of the call will be available until May 23, 2024 at 877-344-7529 (U.S. toll-free), 855-669-9658 (Canada toll-free) or 412-317-0088 (International), with passcode 6247086.

Non-GAAP Financial Measures

Myomo is providing certain financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. This information includes Adjusted EBITDA. This non-GAAP financial measure is not in accordance with, or an alternative for, GAAP and may be different from similar non-GAAP financial measures used by other companies. Myomo believes the use of this non-GAAP financial measure provides supplementary information for investors to use in evaluating operating performance and in comparing Myomo's financial measures with other companies in its industry, many of which present similar non-GAAP financial measures. Adjusted EBITDA is EBITDA adjusted for stock-based compensation expense and loss on equity investment. This non-GAAP financial measure is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP, and should be viewed in conjunction with GAAP financial measures. Investors are encouraged to review the reconciliation of this non-GAAP measure to its most directly comparable GAAP financial measure. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables included as part of this press release.

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the Company's future business expectations, including expectations for second quarter and full year 2024 revenue, expectations regarding materiality of revenues from Medicare Part B patients and expectations for its liquidity and achieving operating cash flow breakeven on a quarterly basis, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

These factors include, among other things:

More information about these and other factors that potentially could affect our financial results is included in Myomo's filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material or adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

(Tables to follow)

 

MYOMO, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

 

 

 

For the Three Months Ended

 

 

 

March 31,

 

 

 

2024

 

 

2023

 

Revenue

 

 

 

 

 

 

Product revenue

 

$

3,754,389

 

 

$

3,446,708

 

 

 

 

 

 

 

 

Cost of revenue

 

 

1,455,345

 

 

 

1,139,074

 

Gross profit

 

 

2,299,044

 

 

 

2,307,634

 

Operating expenses:

 

 

 

 

 

 

Research and development

 

 

956,215

 

 

 

476,991

 

Selling, clinical and marketing

 

 

2,361,845

 

 

 

2,030,551

 

General and administrative

 

 

2,869,751

 

 

 

2,471,057

 

 

 

 

6,187,811

 

 

 

4,978,599

 

 

 

 

 

 

 

 

Loss from operations

 

 

(3,888,767

)

 

 

(2,670,965

)

 

 

 

 

 

 

 

Other (income) expense, net

 

 

 

 

 

 

Interest income, net

 

 

(135,293

)

 

 

(86,314

)

Other expense, net

 

 

?

 

 

 

31

 

Loss on equity investment

 

 

?

 

 

 

17,202

 

 

 

 

(135,293

)

 

 

(69,081

)

Loss before income taxes

 

 

(3,753,474

)

 

 

(2,601,884

)

Income tax expense

 

 

82,158

 

 

 

42,411

 

Net loss

 

$

(3,835,632

)

 

$

(2,644,295

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding:

 

 

 

 

 

 

Basic and diluted

 

 

36,752,597

 

 

 

24,196,732

 

Net loss per share attributable to common stockholders

 

 

 

 

 

 

Basic and diluted

 

$

(0.10

)

 

$

(0.11

)

 

MYOMO, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

 

March 31,

 

 

December 31,

 

 

 

2024

 

 

2023

 

 

 

(unaudited)

 

 

 

 

ASSETS

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

5,434,726

 

 

$

6,871,306

 

Short-term investments

 

 

5,523,664

 

 

 

1,994,662

 

Accounts receivable, net

 

 

1,683,414

 

 

 

2,382,658

 

Inventories, net

 

 

2,386,497

 

 

 

1,803,507

 

Prepaid expenses and other current assets

 

 

676,787

 

 

 

598,850

 

Total Current Assets

 

 

15,705,088

 

 

 

13,650,983

 

Operating lease assets with right of use

 

 

604,897

 

 

 

663,594

 

Equipment, net

 

 

205,917

 

 

 

175,794

 

Other assets

 

 

4,955

 

 

 

91,237

 

Total Assets

 

$

16,520,857

 

 

$

14,581,568

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

Accounts payable and accrued expenses

 

 

4,963,707

 

 

 

4,885,944

 

Current operating lease liability

 

 

421,514

 

 

 

486,143

 

Income taxes payable

 

 

171,280

 

 

 

96,461

 

Deferred revenue

 

 

?

 

 

 

8,510

 

Total Current Liabilities

 

 

5,556,501

 

 

 

5,477,058

 

Non-current operating lease liability

 

 

64,599

 

 

 

115,160

 

Total Liabilities

 

 

5,621,100

 

 

 

5,592,218

 

Commitments and Contingencies

 

 

?

 

 

 

?

 

Stockholders' Equity:

 

 

 

 

 

 

Preferred stock

 

 

?

 

 

 

?

 

Common stock

 

 

2,881

 

 

 

2,715

 

Additional paid-in capital

 

 

111,522,270

 

 

 

105,840,239

 

Accumulated other comprehensive income

 

 

147,511

 

 

 

83,669

 

Accumulated deficit

 

 

(100,766,441

)

 

 

(96,930,809

)

Treasury stock, at cost

 

 

(6,464

)

 

 

(6,464

)

Total Stockholders' Equity

 

 

10,899,757

 

 

 

8,989,350

 

Total Liabilities and Stockholders' Equity

 

$

16,520,857

 

 

$

14,581,568

 

 

MYOMO, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

 

For the Three Months Ended March 31,

 

2024

 

 

2023

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

Net loss

 

$

(3,835,632

)

 

$

(2,644,295

)

Adjustments to reconcile net loss to net cash used in operations:

 

 

 

 

 

 

Depreciation

 

 

29,685

 

 

 

48,632

 

Stock-based compensation

 

 

320,288

 

 

 

171,027

 

Credit losses

 

 

?

 

 

 

13,000

 

Loss on equity investment

 

 

?

 

 

 

17,202

 

Amortization of right-of-use assets

 

 

58,658

 

 

 

101,829

 

Other non-cash charges

 

 

63,930

 

 

 

49,012

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

718,676

 

 

 

340,533

 

Inventories

 

 

(597,087

)

 

 

(157,148

)

Prepaid expenses and other current assets

 

 

6,897

 

 

 

(53,577

)

Accounts payable and accrued expenses

 

 

87,041

 

 

 

386,880

 

Operating lease liabilities

 

 

(115,191

)

 

 

(109,109

)

Deferred revenue

 

 

(11,181

)

 

 

(20,093

)

Net cash used in operating activities

 

 

(3,245,564

)

 

 

(1,816,690

)

CASH USED IN INVESTING ACTIVITIES

 

 

(3,542,565

)

 

 

(45,085

)

CASH PROVIDED BY FINANCING ACTIVITIES

 

 

5,361,909

 

 

 

5,772,057

 

Effect of foreign exchange rate changes on cash

 

 

(10,360

)

 

 

7,311

 

 

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

 

(1,436,580

)

 

 

3,917,593

 

 

 

 

 

 

 

 

Cash and cash equivalents, beginning of period

 

 

6,871,306

 

 

 

5,345,967

 

 

 

 

 

 

 

 

Cash and cash equivalents, end of period

 

$

5,434,726

 

 

$

9,263,560

 

 

MYOMO, INC.

RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

(unaudited)

 

 

 

For the Three Months
Ended March 31,

 

 

 

2024

 

 

2023

 

GAAP net loss

 

$

(3,835,632

)

 

$

(2,644,295

)

Adjustments to reconcile to Adjusted EBITDA:

 

 

 

 

 

 

Interest income, net

 

 

(135,293

)

 

 

(86,314

)

Depreciation expense

 

 

29,685

 

 

 

48,632

 

Stock-based compensation

 

 

320,288

 

 

 

171,027

 

Loss on investment in minority interest

 

 

?

 

 

 

17,202

 

Income tax expense

 

 

82,158

 

 

 

42,411

 

Adjusted EBITDA

 

$

(3,538,794

)

 

$

(2,451,337

)

 


These press releases may also interest you

at 12:04
Aboriginal Peoples: Fact and Fiction, a new, unique and user-friendly website, was launched last night by Institut Tshakapesh and the Commission des droits de la personne et des droits de la jeunesse. The organizations joined forces for this major...

at 12:01
INITIATION NOTE: BrainStorm Cell Therapeutics Inc.  is focused on developing autologous mesenchymal stem cell (MSC) therapies for the treatment of neurodegenerative diseases (NDDs) ? BCLI's primary...

at 12:00
Netflix, Inc. today announced it will post its second quarter 2024 financial results and business outlook on its investor relations website at http://ir.netflix.net on Thursday, July 18, 2024, at approximately 1:00 p.m. Pacific Time....

at 12:00
ResumeBuilder.com, the premier resource for professional resume templates and career advice, has published a recent survey report investigating the prevalence of quiet vacationing among corporate workers. The report also highlights the reasons why...

at 12:00
Entrepreneur, Grammy Award-winning songwriter, and former long-time star of The Real Housewives of Atlanta Kandi Burruss is expanding her already hugely successful retail businesses that offer high-quality cosmetics, intimacy items and other...

at 11:57
Acclaimed actor & author Alan Cumming, currently the host of the global cultural phenomenon The Traitors, is joining PowerToFly's Pride: Championing LGBTQIA+ Leaders & Allies summit for an exclusive fireside chat about his career, his advocacy and...



News published on and distributed by: